Rebus Biosystems Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $17.8M

  • Investors
  • 10

Rebus Biosystems General Information

Description

Developer of an automated spatial omics platform designed to analyze cells at the molecular level while maintaining spatial context. The company focuses on automating microfluidics setup for sequential labeling of expressed transcripts with sensitive and scalable high-resolution imaging, enabling pharmaceutical groups to visualize gene expression profiles across large areas of human brain tissue sections at remarkable speed and without compromising data quality.

Contact Information

Website
www.rebusbio.com
Formerly Known As
LightSpeed Genomics, Solametrix, Optical Biosystems
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2255 Martin Avenue
  • Suite F
  • Santa Clara, CA 95050
  • United States
+1 (408)
Primary Industry
Other Devices and Supplies
Other Industries
Laboratory Services (Healthcare)
Biotechnology
Other Healthcare Technology Systems
Parent Company
LGC Biosearch Technologies
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 2255 Martin Avenue
  • Suite F
  • Santa Clara, CA 95050
  • United States
+1 (408)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rebus Biosystems Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 03-Nov-2022 $17.8M Completed Generating Revenue
5. Later Stage VC (Series B1) 19-Nov-2020 Completed Generating Revenue
4. Merger/Acquisition 25-Sep-2013 Completed Generating Revenue
3. Later Stage VC (Series B) 19-Sep-2012 Completed Generating Revenue
2. Debt - General 01-Jan-2008 $1.9M Completed Generating Revenue
1. Early Stage VC (Series A) 09-Mar-2007 $1.9M $1.9M Completed Generating Revenue
To view Rebus Biosystems’s complete valuation and funding history, request access »

Rebus Biosystems Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C-2
Series C-1
Series C
Series B-1 33,214,518 $0.000100 $0.06 $0.62 $0.62 1x $0.62 29.11%
Series A 8,954,516 $0.000100 $0.06 $0.62 $0.62 1x $0.62 7.85%
To view Rebus Biosystems’s complete cap table history, request access »

Rebus Biosystems Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an automated spatial omics platform designed to analyze cells at the molecular level while maintaining spat
Other Devices and Supplies
Santa Clara, CA
14 As of 2024

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rebus Biosystems Competitors (1)

One of Rebus Biosystems’s competitors is Vizgen, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vizgen Venture Capital-Backed Cambridge, MA
You’re viewing 1 of 1 competitors. Get the full list »

Rebus Biosystems Patents

  • 32

    Total Documents Applications and Grants

  • Total Patents Families

  • 24

    Granted

  • Pending

  • Expiring in next 12 mo

Rebus Biosystems Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11366303-B2 Method for detecting particles using structured illumination Active 30-Jan-2018
US-20220334368-A1 Method for detecting particles using structured illumination Active 30-Jan-2018
EP-3747189-A4 Method for detecting particles using structured illumination Inactive 30-Jan-2018
EP-3747189-A1 Method for detecting particles using structured illumination Inactive 30-Jan-2018
US-20190235222-A1 Method for detecting particles using structured illumination Active 30-Jan-2018 G02B21/367
To view Rebus Biosystems’s complete patent history, request access »

Rebus Biosystems Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Rebus Biosystems FAQs

  • When was Rebus Biosystems founded?

    Rebus Biosystems was founded in 2006.

  • Where is Rebus Biosystems headquartered?

    Rebus Biosystems is headquartered in Santa Clara, CA.

  • What is the size of Rebus Biosystems?

    Rebus Biosystems has 14 total employees.

  • What industry is Rebus Biosystems in?

    Rebus Biosystems’s primary industry is Other Devices and Supplies.

  • Is Rebus Biosystems a private or public company?

    Rebus Biosystems is a Private company.

  • What is the current valuation of Rebus Biosystems?

    The current valuation of Rebus Biosystems is .

  • What is Rebus Biosystems’s current revenue?

    The current revenue for Rebus Biosystems is .

  • How much funding has Rebus Biosystems raised over time?

    Rebus Biosystems has raised $37.8M.

  • Who are Rebus Biosystems’s competitors?

    Vizgen is a competitor of Rebus Biosystems.

  • When was Rebus Biosystems acquired?

    Rebus Biosystems was acquired on 03-Nov-2022.

  • Who acquired Rebus Biosystems?

    Rebus Biosystems was acquired by LGC Biosearch Technologies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »